| Literature DB >> 27040698 |
Katrien Van Roosbroeck1, George A Calin2.
Abstract
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease and has a highly variable clinical course with survival ranging from a couple of months to several decades. MicroRNAs (miRNAs), small non-coding RNAs that regulate transcription and translation of genes, have been found to be involved in CLL initiation, progression, and resistance to therapy. In addition, they can be used as prognostic biomarkers and as targets for novel therapies. In this review, we describe the association between miRNAs and the cytogenetic aberrations commonly found in CLL, as well as with other prognostic factors. We describe the presence of miRNAs as extracellular entities in the plasma and serum of CLL patients and discuss their role in resistance to therapy. Finally, we will explore the potential of targeted miRNA therapy for the treatment of CLL, with a special emphasis on MRX34, the first miRNA mimic that is currently being evaluated for clinical use.Entities:
Keywords: Biomarker; Chronic lymphocytic leukemia; MicroRNA; Targeted therapy; miR-34 mimic
Mesh：
Substances：
Year: 2016 PMID： 27040698 PMCID： PMC5533104 DOI： 10.1053/j.seminoncol.2016.02.015
Source DB: PubMed Journal: Semin Oncol ISSN： 0093-7754 Impact factor: 4.929